

Table S1. Summary characteristics of studies on preference elicitation in psoriasis management

| Variables  | n (%)   |
|--|---------|
| Study population <sup>a</sup>                                  |         |
| Psoriasis/atopic dermatitis patients                           | 2 (9)   |
| Psoriasis patients   | 16 (70) |
| Psoriasis/atopic eczema patients                               | 2 (9)   |
| Psoriasis/melanoma patients                                    | 1 (4)   |
| Dermatologist  | 1 (4)   |
| Psoriasis arthritis patients                                   | 1 (4)   |
| Study setting  |         |
| Outpatient hospital clinic                                     | 8 (35)  |
| Inpatient hospital clinic                                      | 1 (4)   |
| Home   | 3 (13)  |
| General practice   | 1 (4)   |
| Unclear  | 10 (44) |
| Study country  |         |
| Canada   | 1 (4)   |
| Denmark  | 3 (13)  |
| Germany  | 3 (13)  |
| The Netherlands  | 1 (4)   |
| Sweden   | 3 (13)  |
| USA  | 5 (22)  |
| UK   | 5 (22)  |
| Unclear  | 2 (9)   |
| Years of publication   |         |
| 1981–1990  | 3 (13)  |
| 1991–2000  | 9 (39)  |
| 2001–2010  | 11 (48) |
| Preference elicitation method <sup>b</sup>                     |         |
| Binary   | 8 (23)  |
| Ordinal scale  | 1 (3)   |
| Willingness-to-pay   | 8 (23)  |
| Time trade-off   | 5 (15)  |
| Visual analogue scale  | 3 (9)   |
| Standard gamble  | 2 (6)   |
| Discrete choice experiment                                     | 3 (9)   |
| Rating   | 2 (6)   |
| Ranking  | 1 (3)   |
| Paired comparison  | 1 (3)   |
| Focus of preference elicitation (primary outcome) <sup>c</sup> |         |
| Preferences for treatment options                              | 9 (33)  |
| Preferences for treatment attributes                           | 13 (48) |
| Preferences for different health states                        | 3 (11)  |
| Preferences for different health states domains                | 2 (8)   |

<sup>a</sup>In most cases, study population consists of other patient groups in addition to psoriasis patients.

<sup>b</sup>More than one preference elicitation method may apply to a study.

<sup>c</sup>More than one primary outcome may apply to the same study.